SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1957-01-01
- Employees
- 1.3K
- Market Cap
- -
- Website
- http://www.snbl.co.jp
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Phase 2
Completed
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
- Target Recruit Count
- 68
- Registration Number
- NCT00787566
- Locations
- 🇺🇸
The study is conducted at 14 Centers, in 14 cities accross the United States, The study is managed by Kendle International, in Wilmington, North Carolina, United States
News
No news found